Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device

Christos Zormpas1 · Jörg Eiringhaus1 · Henrike A. K. Hillmann1 · Stephan Hohmann1 · Johanna Müller-Leisse1 · Jan D. Schmitto2 · Christian Veltmann1 · David Duncker1

Received: 28 April 2020 / Accepted: 22 June 2020 / Published online: 1 July 2020
© The Author(s) 2020

Abstract

Purpose The subcutaneous implantable cardioverter-defibrillator (S-ICD) could be a promising alternative to the conventional transvenous ICD in patients with LVAD due to its reduced risk of infection. However, surface ECG is altered following LVAD implantation and, since S-ICD detection is based on surface ECG, S-ICD could be potentially affected. The aim of the present study was to analyze S-ICD eligibility in patients with LVAD.

Methods Seventy-five patients implanted with an LVAD were included in this prospective single-center study. The ECG-based screening test and the automated screening test were performed in all patients.

Results Fifty-five (73.3%) patients had either a positive ECG-based or automated screening test. Out of these, 28 (37.3%) patients were found eligible for S-ICD implantation with both screening tests performed. ECG-based screening test was positive in 50 (66.6%) patients; automated screening test was positive in 33 (44.0%) patients. Three ECG-based screening tests could not be evaluated due to artifacts. With the automated screening test, in 9 (12.0%) patients, the test yielded no result.

Conclusions Patients implanted with an LVAD showed lower S-ICD eligibility rates compared with patients without LVAD. With an S-ICD eligibility rate of maximal 73.3%, S-ICD therapy may be a feasible option in these patients. Nevertheless, S-ICD implantation should be carefully weighed against potential device-device interference. Prospective studies regarding S-ICD eligibility before and after LVAD implantation are required to further elucidate the role of S-ICD therapy in this population.

Keywords ICD · S-ICD · LVAD · Device-device interference · S-ICD screening test

1 Introduction

Implantable cardioverter-defibrillators (ICDs) represent an established therapy to reduce sudden cardiac death in patients with symptomatic heart failure and reduced left ventricular function [1]. Implantation of left ventricular assist devices (LVAD) in patients with end-stage heart failure has led to a significant improvement in survival rates and patient’s quality of life [2, 3]. The implantation was initially meant as bridge to transplantation, though in recent years the procedure is increasingly performed as destination therapy [2]. Since LVAD implantation is performed in advanced heart failure, in most of the patients, an ICD is indicated.

Conventional transvenous ICD systems carry a significant risk for peri-procedural complications, such as pneumothorax, pericardial effusion, hemothorax, and lead dislodgement and also for chronic complications, including endocarditis, thrombosis, and lead failure [4–6]. In order to avoid these complications, subcutaneous ICD (S-ICD) systems have been developed [7]. S-ICD therapy has been shown to be a safe and effective alternative to the transvenous ICD [8].

ICD therapy in LVAD patients can be challenging and several studies have reported serious side effects derived from the co-existence of ICD and LVAD, including lead failure and telemetry failure [9, 10]. Especially, device-device interferences have been reported in patients with LVAD implanted with an S-ICD [11–13].

The advantage of the S-ICD is the avoidance of transvenous intracardiac leads, which could be particularly beneficial in patients with an LVAD. Adequate S-ICD sensing is based on the subcutaneous lead and relies on good discrimination between P,
R, and T waves. Electrocardiographic changes may occur after LVAD implantation [14] which consecutively may impact proper sensing of the S-ICD system and thus S-ICD eligibility (Fig. 1). ECG-based S-ICD screening test interpretation can be challenging in patients with LVAD.

The aim of the present study was to evaluate S-ICD eligibility in patients implanted with an LVAD using the available screening methods and to identify parameters affecting S-ICD eligibility in these patients.

2 Methods

Consecutive patients implanted with an LVAD at Hannover Medical School presenting for routine follow-up were included in the study in a prospective non-randomized manner. The study complied with the Declaration of Helsinki and was approved by the local ethics committee. All patients gave written informed consent.

Baseline parameters were recorded including body mass index (BMI) and chest circumference. A standard 12-lead ECG was performed in all patients in accordance with international standards [15].

2.1 S-ICD screening procedure

In all patients, the two available S-ICD screening tests were performed to evaluate S-ICD eligibility: (1) an ECG-based S-ICD screening and (2) an automated S-ICD screening test.

For the ECG-based screening test, standard ECG limb electrodes (LA, RA, LL) were placed as follows (Fig. 2a): (1) 1 cm lateral to the xiphoid process (LA), left and right parasternal, respectively, (2) 14 cm cranial to the first electrode (RA), and (3) on the left mid-axillary line, 5th or 6th intercostal space (LL). The neutral electrode was placed on the right lower abdominal wall. With this electrode configuration, S-ICD sensing vectors were simulated in the left parasternal and right parasternal position as depicted in Fig. 3. For each patient, screening test was performed in supine and erect positions. For the ECG-based screening, recordings were obtained at gains of 5, 10, and 20 mV at a paper speed of 25 mm/s using an ECG device (MAC 5500, GE Healthcare, Chicago, IL, USA).

Fig. 1 Twelve-lead ECG of a patient with an implanted LVAD (HVAD). Typical ECG characteristics: high-frequency artifacts particularly in leads I, III, as well as V5 and V6 and low QRS amplitude [14]
**Fig. 3** Chest X-ray of a patient with an implanted S-ICD in the left parasternal position. The 3 possible vectors formed from the S-ICD lead and the S-ICD can are depicted. Red colored are the vectors formed in the left parasternal position and blue colored are the vectors formed in the right parasternal position. RA, right arm; LA, left arm; LL, left leg.
Regarding automated screening, vector eligibility was determined from the manufacturer screening template (Latitude Programmer Model 3120, Boston Scientific, Natick, MA, USA). Positioning of the electrodes was performed analog to the ECG-based screening (Fig. 2b).

2.2 S-ICD eligibility

The ECG-based screening test was considered positive if screening template passed in at least one lead in both supine and erect positions at any gain in either left parasternal or right parasternal position. For the automated screening test, S-ICD eligibility was determined automatically if at least one vector was found eligible in both supine and erect position in either left parasternal or right parasternal position.

2.3 Statistical analysis

Categorical variables are presented as numbers and percentages and were compared among subgroups using the chi-square test or the Fisher’s exact test accordingly. Continuous variables are presented as mean ± standard deviation. Differences among continuous variables were compared using an unpaired t test. Values of p < 0.05 were considered statistically significant. Statistical analysis was conducted using GraphPad PRISM 6 software (GraphPad Software, Inc., CA, USA).

3 Results

The study population consisted of 75 patients included between September 2016 and February 2017. Baseline characteristics are shown in Table 1. Inclusion in the study occurred in median 873.5 days after LVAD implantation.

3.1 Electrocardiographic characteristics

Twelve-lead ECG was available for all patients. Three out of 75 ECGs (4%) showed extensive artifacts from the LVAD and were excluded from the ECG analysis. Twenty-one (29.1%) patients had a paced QRS complex and 51 (70.9%) patients had an intrinsic QRS complex. Table 2 summarizes the 12-lead ECG parameters analyzed.

3.2 S-ICD eligibility

Overall 900 S-ICD ECGs, namely 2700 potential vectors, were evaluated for eligibility. Using the ECG-based screening test, 3 (4%) tests could not be analyzed due to manifest artifacts from the LVAD and were therefore considered negative. Performance of automated screening in 9 (12%) patients yielded no result despite multiple attempts, and thus the test was considered negative.

| Parameter                                         | n = 75 |
|---------------------------------------------------|--------|
| Age (years)                                       | 59.4 ± 9.7 |
| Male (n, %)                                       | 63 (84.0) |
| Chest circumference (cm)                         | 106.5 ± 12.0 |
| Body mass index (kg/m²)                          | 28.0 ± 5.8 |
| Etiology of cardiomyopathy (n, %)                 |        |
| Dilated cardiomyopathy                            | 45 (60.0) |
| Ischemic cardiomyopathy                           | 26 (34.6) |
| Other                                             | 4 (5.4) |
| Prior cardiac surgery (n, %)                      | 52 (69.3) |
| Implant ICD (n, %)                                | 73 (97.3) |
| Pacemaker dependent (n, %)                        | 5 (6.6) |
| Pacing percentage (n, %)                          |        |
| < 1%                                              | 47 (62.7) |
| 1–80%                                             | 6 (8.0) |
| > 80%                                             | 22 (29.3) |
| LVAD type (n, %)                                  |        |
| HVAD                                              | 48 (64.0) |
| HeartMate III                                    | 14 (18.7) |
| HeartMate II                                     | 11 (14.6) |
| HeartAssist5                                      | 2 (2.7) |
| Minimal invasive LVAD operation technique (n, %)  | 34 (45.3) |

| Parameter                                         | n = 72 |
|---------------------------------------------------|--------|
| Atrial rhythm (n, %)                              |        |
| Sinus rhythm                                      | 48 (66.7) |
| Atrial fibrillation                               | 23 (31.9) |
| Paced                                             | 1 (1.4) |
| Heart rate (bpm)                                  | 76.1 ± 20.5 |
| Cardiac axis (°)                                  | −29.0 ± 98.3 |
| PR interval (ms) (n = 48)                         | 176.5 ± 48.2 |
| QRS duration (ms)                                 | 130.5 ± 45.3 |
| QRS morphology (n, %)                             |        |
| No BBB                                            | 25 (34.7) |
| LBBB                                             | 15 (20.8) |
| RBBB                                             | 7 (9.8) |
| IVCD                                             | 4 (5.6) |
| Paced                                            | 21 (29.1) |
| QTc interval (ms)                                 | 485.0 ± 58.5 |
Overall, 55 (73.3%) patients had either a positive ECG-based or automated screening test. Twenty-eight (37.3%) patients were found eligible for S-ICD implantation with both screening tests performed, of which 23 (30.7%) had ≥2 eligible vectors. Two patients (2.6%) found ineligible in left parasternal position were found eligible in the right parasternal position.

Fifty (66.6%) patients were eligible for S-ICD implantation using the ECG-based screening test and 33 (44.0%) patients were eligible with the automated screening test (Fig. 4). Table 3 provides a detailed overview of the S-ICD eligibility results in the different parasternal positions studied and according to the screening test performed.

### 3.3 Reasons for failure of S-ICD screening

With the ECG-based screening test, a total of 2700 S-ICD vector ECGs were analyzed, from which 2168 (80.3%) delivered a negative result. Reasons for failure were a low amplitude of the QRS complex ($n = 1080, 49.8\%$), T wave oversensing ($n = 699, 32.2\%$), high amplitude of the QRS complex ($n = 357, 16.5\%$), oversensing of the following P wave ($n = 25, 1.2\%$), and a broad QRS complex not fitting in the QRS-T-wave shell of the screening tool ($n = 7, 0.3\%$).

In 9 (12%) patients, the automated screening test yielded no result and was consequently considered negative. Reasons for failure of the automated screening test are not provided by the programming device.

### 3.4 Factors affecting S-ICD eligibility

In order to evaluate factors which could potentially affect S-ICD eligibility, eligible ($n = 55$) and ineligible ($n = 20$) patients were compared. Table 4 shows an overview of the analyzed parameters comparing both groups. No significant difference was found in any of the analyzed baseline parameters.

### 4 Discussion

The present study is the first study to assess S-ICD eligibility in a large cohort of patients implanted with LVAD. The main results are as follows:

1. 73.3\% of patients with LVAD were eligible for S-ICD implantation either with the ECG-based or the automated screening test.

Table 3  Eligible vectors in the different parasternal positions according to the screening method performed in 75 patients

| Eligible vectors | ECG-based screening test, left parasternal ($n, \%$) | ECG-based screening test, right parasternal ($n, \%$) | Automated screening test, left parasternal ($n, \%$) | Automated screening test, right parasternal ($n, \%$) |
|------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 0                | 27 (36.0)                                     | 41 (54.7)                                     | 45 (60.0)                                     | 56 (74.7)                                     |
| 1                | 25 (33.3)                                     | 18 (24.0)                                     | 11 (14.7)                                     | 7 (9.3)                                       |
| 2                | 20 (26.7)                                     | 14 (18.6)                                     | 14 (18.6)                                     | 11 (14.7)                                     |
| 3                | 3 (4.0)                                       | 2 (2.7)                                       | 5 (6.7)                                       | 1 (1.3)                                       |
2. S-ICD eligibility rate of patients with LVAD was higher (66.6%) using the ECG-based screening test in comparison with the automated screening test (44%).

Patients with LVAD may develop device-related (ICD and/or LVAD) infections necessitating extraction of the implanted system [10, 16, 17]. In case of a device infection or lead failure requiring the extraction of the complete ICD system including intracardiac leads, studies have shown a considerable morbidity and mortality [18, 19]. Thus, in these patients, implantation of an S-ICD might be beneficial and could be considered [20]. In patients with LVAD, lack of transvenous access due to abandoned leads and/or recurrent central venous catheters resulting in occlusion of the subclavian veins can pose an important limiting factor in case of lead revision. Thus, S-ICD implantation can overcome several disadvantages of the conventional transvenous ICDs (infection, bleeding, extraction-related complications).

LVAD implantation leads to significant changes of the surface ECG [14, 21]. Moreover, heart failure is a progressive disease which can lead to further ECG alterations [22]. Thus, the S-ICD screening test and consequently S-ICD eligibility could be affected by changes in amplitude and vector of the QRS complex.

The present study shows reduced S-ICD eligibility rates (66.6% with the ECG-based and 44% with the automated screening test) in patients with LVAD compared with previously reported rates in patients with heart failure [23–26].

### Table 4 Comparison of baseline parameters between eligible and ineligible patients for S-ICD

| Parameter                                | Ineligible, n = 20 | Eligible, n = 55 | p value |
|------------------------------------------|--------------------|------------------|---------|
| Age (years)                              | 59.2 ± 7.1         | 59.5 ± 10.3      | 0.920   |
| Male (n, %)                              | 18 (90.0)          | 45 (81.8)        | 0.497   |
| Chest circumference (cm)                 | 107.9 ± 9.7        | 106.2 ± 13.1     | 0.533   |
| Body mass index (kg/m²)                  | 27.6 ± 5.4         | 28.2 ± 6.1       | 0.693   |
| Etiology of cardiomyopathy (n, %)        |                    |                  |         |
| Dilated cardiomyopathy                   | 12 (60.0)          | 33 (60.0)        | 0.402   |
| Ischemic cardiomyopathy                  | 7 (35.0)           | 19 (34.5)        | 0.705   |
| Other                                    | 1 (5.0)            | 3 (5.5)          | 0.997   |
| Prior cardiac surgery (n, %)             | 12 (60.0)          | 40 (72.7)        | 0.396   |
| LVAD type (n, %)                         |                    |                  |         |
| HVAD                                     | 14 (70.0)          | 34 (61.8)        | 0.299   |
| HeartMate III                           | 3 (15.0)           | 11 (20)          | 0.857   |
| HeartMate II                            | 3 (15.0)           | 8 (14.5)         | 0.966   |
| HeartAssist5                             | 0                  | 2 (3.7)          | 0.999   |
| Minimal invasive operation technique (n, %) | 10 (50.0)          | 24 (43.6)        | 0.794   |
| Atrial rhythm (n, %)                     |                    |                  |         |
| Sinus rhythm                             | 13 (68.4)          | 32 (60.4)        | 0.832   |
| Atrial fibrillation                      | 6 (31.6)           | 20 (37.7)        | 0.799   |
| Paced                                    | 0                  | 1 (1.9)          | 0.999   |
| Heart rate (bpm)                         | 82.1 ± 13.2        | 75.4 ± 13.7      | 0.094   |
| Cardiac axis (°)                         | −52.7 ± 75.0       | −16.6 ± 107.3    | 0.097   |
| QRS duration (ms)                        | 134.1 ± 42.9       | 129.8 ± 35.4     | 0.705   |
| QRS morphology (n, %)                    |                    |                  |         |
| No BBB                                   | 7 (36.8)           | 18 (33.9)        | 0.124   |
| LBBB                                     | 4 (21.1)           | 11 (20.8)        | 0.388   |
| RBBB                                     | 0                  | 7 (13.2)         | 0.388   |
| IVCD                                     | 1 (5.3)            | 3 (5.7)          | 0.984   |
| Paced                                    | 7 (36.8)           | 14 (26.4)        | 0.388   |
| QTc interval (ms)                        | 471.2 ± 56.5       | 490.1 ± 59.4     | 0.427   |
| R:T ratio in lead I                      | 13.7 ± 16.8        | 9.2 ± 15.9       | 0.319   |
| R:T ratio in lead II                     | 6.6 ± 11.3         | 7.7 ± 12.4       | 0.724   |
| R:T ratio in lead aVF                    | 6.9 ± 11.4         | 6.5 ± 11.3       | 0.879   |
et al. studied 230 patients with an ICD (primary or secondary prevention) and showed a positive ECG-based screening test in 92.6% of the patients [24]. Similarly, Randles et al. analyzed 196 patients with either primary or secondary preventive indication for ICD therapy and reported S-ICD eligibility rates with the ECG-based screening test of 85.2% [26]. Lower eligibility rates in the present study could be attributed to ECG altering effect of both, the LVAD device itself, the progressive character of end-stage heart failure and the high percentage of patients (29.1%) with a paced QRS complex.

Eligibility for S-ICD in the present study was determined, according to manufacturer’s recommendations, as at least on eligible vector in any of the two screening tests performed. Since S-ICD performance and efficacy in patients with LVAD are poorly known, S-ICD eligibility with both screening tests as well as the ≥2 vector rule should be met before considering implantation of an S-ICD in the presence of LVAD. If these two rules are to be applied, the eligibility rates found in the present study are much lower (30.7%). In line with these findings, several case reports of inappropriate ICD therapy in patients with an S-ICD after LVAD implantation have been reported leading to major concerns regarding the safety in case of co-existence of an LVAD and an S-ICD [11, 27, 28]. An additional restricting factor for S-ICD implantation is the lack of antidibradycardia therapy, which may be intermittently necessary in some patients. In the present study, 21 (29.1%) patients had a paced QRS complex, although only 5 (6.8%) patients were actually pacemaker dependent. Previous studies have shown slightly reduced S-ICD eligibility rates in patients with CRT or pacemaker devices [29–31]. Giammaria et al. studied S-ICD eligibility in 48 CRT carriers and showed S-ICD eligibility rates of 71% [29]. In the present study, 29.1% of the patients had a paced QRS complex, notwithstanding that the presence of a paced QRS complex did not significantly affect S-ICD eligibility.

Even though only a very small fraction of the patients included were pacemaker dependent (6.8%), it is unclear to which extent intermittent pacing may still be required. Also CRT in non-pacemaker-dependent patients may have a positive effect even in the presence of LVAD, although not adequately studied. The fact that S-ICD lacks also the ability to deliver antidibradycardia pacing (ATP) is of great importance for patients with LVAD as they most of the times hemodynamically tolerate VT and thus are conscious in case of high-energy shock delivery.

Clinical performance of S-ICD in patients with LVAD, including proper baseline sensing as well as sensing during arrhythmia, is unknown, particularly when taking into consideration the changing intravascular volume status and electrolyte balance. Major concerns have been also raised regarding defibrillation success after S-ICD pulse generator replacement [32] and the high DFT energy required. Thus, S-ICD eligibility should not be confused with S-ICD efficacy, which was not evaluated in the present study.

In the present study, 12% of the patients with LVAD examined with the automated screening test yielded no result. We hypothesize that this observation was caused by artifacts produced from the LVAD.

Comparison of patients showing eligibility vs. ineligibility did not reveal any significant predictors for S-ICD screening failure. Especially, neither ECG parameters nor the LVAD type or implant technique affected S-ICD eligibility.

In a previous study of 215 patients with LVAD, in which 12-lead ECGs before and after LVAD implantation were analyzed, significant changes of the R:T ratio in leads I, II, and aVF after LVAD implantation were reported [14]. Groh et al. studied 100 patients with an implanted ICD without antidibradycardia indication, thus potential S-ICD candidates. Among others, they were able to show the importance of T wave in leads I, II, and aVF of the 12-lead ECG regarding S-ICD eligibility, since T wave inversion in these leads was associated with a 23-fold higher likelihood for S-ICD ineligibility [23]. In the present study, no significant difference in the R:T ratio in leads I, II, and aVF was observed between eligible and ineligible patients.

Further studies comparing S-ICD eligibility before and after LVAD implantation are necessary to elucidate whether these findings are due to the underlying end-stage heart failure or LVAD implantation alone.

4.1 Limitations

The present study is the first to assess S-ICD eligibility in a large cohort of 76 patients with LVAD. It has, however, several limitations. The S-ICD screening tests performed represent a single time point of S-ICD eligibility in median 873 days after LVAD implantation. Thus, it remains unclear to which extent the observed findings are only due to LVAD implantation or progression of the underlying disease. We could not assess eligibility before LVAD implantation and how LVAD implantation affects S-ICD eligibility in each patient. The S-ICD screening test performed in this study did not lead to consecutive S-ICD implantation. Thus, the actual S-ICD failure rates could not be confirmed, especially potential device-device interference in case of an implanted S-ICD, as described in case reports previously [11, 12].

Moreover, in the present study, we observed a quite high percentage (29.1%) of patients with paced QRS complex, which are not primarily considered for S-ICD implantation.

When focusing on each S-ICD screening method alone, it should be emphasized that the ECG-based screening test is an examiner-dependent test, in particular in patients with LVAD due to frequently co-existent artifacts. The automated screening, on the other hand, provides a dichotomic result regarding S-ICD eligibility without any explanation of the reason for failure.
5 Conclusion

Patients implanted with an LVAD show an S-ICD eligibility rate of maximal 73.3%. This S-ICD eligibility rate is lower in comparison to patients with heart failure without LVAD. Nevertheless, S-ICD implantation seems to be a feasible alternative for patients with LVAD in selected cases. In patients with end-stage heart failure, in which implantation of an LVAD may become necessary in the near future, implantation of an S-ICD should be carefully weighed against competing risks, since device-device interference can become a significant problem in case of S-ICD implantation. In these individual cases, extensive S-ICD screening testing should be performed to prevent S-ICD failure. Prospective studies are required to further evaluate potential changes in S-ICD eligibility rates after LVAD implantation.

Availability of data and material All data are available in the Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.

Funding Information Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest CZ received travel grants and a fellowship grant from Biotronik and Medtronic. JML received travel grants and a fellowship grant from Abbott. SH received a travel grant from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Medtronic, Microport, and Zoll. JE, HAKH, and JDS do not report any financial disclosures.

Ethics approval The study was approved by the local ethics committee.

Consent to participate Informed consent was obtained from all patients included in the study.

Consent to publish Informed consent was obtained from all patients to publish their data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borrgreffe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europe. Eur Heart J. 2015;36(41):2793–867. https://doi.org/10.1093/eurheartj/ehv316.
2. Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017;19(5):595–602. https://doi.org/10.1002/ejhf.779.
3. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241–8. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963991.
4. Krahn AD, Lee DS, Birnie DS, Healey JS, Crystal E, Dorian P, et al. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: results from the Ontario ICD database. Circ Arrhythm Electrophysiol. 2011;4(2):136–42. https://doi.org/10.1161/CIRCEP.110.959791.
5. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115(19):2474–80. https://doi.org/10.1161/CIRCULATIONAHA.106.663807.
6. van der Heijden AC, Borleffs CJ, Buiten MS, Thijssen J, van Rees JB, Cannegieter SC, et al. The clinical course of patients with implantable cardioverter-defibrillators: extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm. 2015;12(6):1169–76. https://doi.org/10.1016/j.hrthm.2015.02.035.
7. Bardy GH, Smith WM, Hood MA, Crozier JG, Melton IC, Jordens L, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363(1):36–44. https://doi.org/10.1056/NEJMoa0909545.
8. Burke MC, Gold MR, Knight BP, Barr CS, Thenus DA, Boersma LV, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65(16):1605–15. https://doi.org/10.1016/j.jacc.2015.02.047.
9. Kuhne M, Sakumura M, Reich SS, Sarrazin JF, Wells D, Chalfoun N, et al. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure. Am J Cardiol. 2010;105(3):378–82. https://doi.org/10.1016/j.amjcard.2009.09.044.
10. Boulet J, Massie E, Mondesert B, Lamarche Y, Carrier M, Ducharme A. Current review of implantable cardioverter defibrillator use in patients with left ventricular assist device. Curr Heart Fail Rep. 2019;16(6):229–39. https://doi.org/10.1007/s11897-019-00449-8.
11. Pfef1er TJ, König T, Duncker D, Michalski R, Hoffmann S, Oswald H, et al. Subcutaneous implantable cardioverter-defibrillator shocks after left ventricular assist device implantation. Circ Arrhythm Electrophysiol. 2016;9(11). https://doi.org/10.1161/CIRCEP.116.004633.
12. Lopez-Gil M, Fontenla A, Delgado JF, Rodriguez-Muñoz D. Subcutaneous implantable cardioverter defibrillators in patients with left ventricular assist devices: case report and comprehensive review. Eur Heart J - Case Rep. 2019;3. https://doi.org/10.1093/ejcr/zyt057.
13. Zeitler EP, Friedman DJ, Loring Z, Campbell KB, Goldstein SA, Wegernann ZK, et al. Complications involving the subcutaneous implantable cardioverter-defibrillator: lessons learned from
14. Zornapas C, Mueller-Leisse J, Koenig T, Schmittd JD, Veltermann C, Duncker D. Electrocardiographic changes after implantation of a left ventricular assist device – potential implications for subcutaneous defibrillator therapy. J Electrocardiol. 2019;52:29–34. https://doi.org/10.1016/j.jelectrocard.2018.11.002.

15. Klugfield P, Gettes LS, Bailey J, Childers R, Deal BJ, Hancock EW, et al. Standardization and interpretation of the electrocardiogram. J Am Coll Cardiol. 2007;49:1109–27. https://doi.org/10.1016/j.jacc.2007.01.024.

16. Xie A, Phan K, Yan TD. Durability of continuous-flow left ventricular assist devices: a systematic review. Ann Cardiothorac Surg. 2014;3(6):547–56. https://doi.org/10.3978/j.issn.2225-319X.2014.11.01.

17. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495–504. https://doi.org/10.1016/j.healun.2015.10.003.

18. Hauser RG, Katsiyiannis WT, Gornick CC, Almquist AK, Kallinen LM. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. Europace. 2010;12(3):395–401. https://doi.org/10.1093/europace/eup375.

19. Gomes S, Cranney G, Bennett M, Giles R. Long-term outcomes following transvenous lead extraction. Pacing Clin Electrophysiol. 2016;39(4):345–51. https://doi.org/10.1111/pace.12812.

20. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), th. EP Europace. 2019;22:515–49. https://doi.org/10.1093/europace/euz246.

21. Martínez SC, Fansler D, Lai J, Novak EL, Joseph SM, Kleiger RE. Characteristics of the electrocardiogram in patients with continuous-flow left ventricular assist devices. Ann Noninvasive Electrocardiol. 2015;20(1):62–8. https://doi.org/10.1111/ane.12181.

22. Kataoka H, Madias JE. Changes in the amplitude of electrocardiogram QRS complexes during follow-up of heart failure patients. J Electrocardiol. 2011;44(3):394 e1–9. https://doi.org/10.1016/j.jelectrocard.2010.12.160.

23. Groh CA, Sharma S, Pelchovitz DJ, Bhave PD, Rhyner J, Verma N, et al. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014;11(8):1361–6. https://doi.org/10.1016/j.hrthm.2014.04.025.

24. Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, de Groot JR, Rosenmoller B, Wilde AAM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol. 2014;25(5):494–9. https://doi.org/10.1111/jce.12343.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.